hologic , inc .
notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .
it was determined that only customer relationship , trade name , developed technology and know how and in-process research and development had separately identifiable values .
customer relationship represents suros large installed base that are expected to purchase disposable products on a regular basis .
trade name represents the suros product names that the company intends to continue to use .
developed technology and know how represents currently marketable purchased products that the company continues to resell as well as utilize to enhance and incorporate into the company 2019s existing products .
the estimated $ 4900 of purchase price allocated to in-process research and development projects primarily related to suros 2019 disposable products .
the projects were at various stages of completion and include next generation handpiece and site marker technologies .
the company has continued to work on these projects and they are substantially complete as of september 27 , 2008 .
the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets , and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes , partially offset by acquired net operating loss carry forwards that the company believes are realizable .
for all of the acquisitions discussed above , goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired .
the company determined that the acquisition of each aeg , biolucent , r2 and suros resulted in the recognition of goodwill primarily because of synergies unique to the company and the strength of its acquired workforce .
supplemental unaudited pro-forma information the following unaudited pro forma information presents the consolidated results of operations of the company , r2 and suros as if the acquisitions had occurred at the beginning of fiscal 2006 , with pro forma adjustments to give effect to amortization of intangible assets , an increase in interest expense on acquisition financing and certain other adjustments together with related tax effects: .

2006
Net revenue
$524,340
Net income
$28,649
Net income per share—basic
$0.28
Net income per share—assuming dilution
$0.17

the $ 15100 charge for purchased research and development that was a direct result of these two transactions is excluded from the unaudited pro forma information above .
the unaudited pro forma results are not necessarily indicative of the results that the company would have attained had the acquisitions of both r2 and suros occurred at the beginning of the periods presented .
4 .
acquisition of intangible assets on september 29 , 2005 , pursuant to an asset purchase agreement between the company and fischer imaging corporation ( 201cfischer 201d ) , dated june 22 , 2005 , the company acquired the intellectual property and customer lists relating to fischer 2019s mammography business and products for $ 26900 in cash and cancellation of the principal and interest outstanding under a $ 5000 secured loan previously provided by the company to fischer .
the aggregate purchase price for the fischer intellectual property and customer lists was approximately $ 33000 , which included approximately $ 1000 related to direct acquisition costs .
in accordance with emerging issues task force issue no .
98-3 , determining whether a non-monetary transaction involved receipt of .

Question: Analyse this data from a financial earnings document. what would pro forma net income have been if the charge for purchased research and development had been expensed?
Choices:
28620
43749
13549.0
0
-14770
Correct choice index: 2